Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lara MA, Martin-Malo A, Aljama-Garcia P. New alternatives in the treatment of myeloma kidney. Nefrologia. 2013;33:443–447.
   PubMed Web of Science ®Google Scholar
• Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8:2007–2017.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–987.
   PubMed Web of Science ®Google Scholar
• Leung N, Nasr SH. Myeloma-related kidney disease. Adv Chronic Kidney Dis. 2014;21:36–47.
   PubMed Web of Science ®Google Scholar
• Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533–2545.
   PubMed Web of Science ®Google Scholar
• Stompor T, Zablocki M, Pankrac K. Renal involvement in multiple myeloma. Pol Arch Med Wewn. 2012;122:443–448.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–1493.
   PubMed Web of Science ®Google Scholar
• Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail. 2000;22:465–477.
   PubMed Web of Science ®Google Scholar
• Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
   PubMed Web of Science ®Google Scholar
• Loboz KK, Shenfield GM. Drug combinations and impaired renal function – the 'triple whammy.' Br J Clin Pharmacol. 2005;59:239–243.
   PubMed Web of Science ®Google Scholar
• Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013;42:684–688.
   PubMed Web of Science ®Google Scholar
• Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma. 2011;52:2299–2303.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28:4976–4984.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544–1557.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–429.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–1893.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129–1136.
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis nordic myeloma study group. Eur J Haematol. 2000;65:175–181.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–549.
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Mazzone C, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118:5759–5766.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol. 2013;139:1937–1946.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Rauch E, Kuehr T, et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica.2015;100:385–391.
   PubMed Web of Science ®Google Scholar
• Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937 + I-40.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.
   PubMed Web of Science ®Google Scholar
• Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002–medical research council adult leukaemia working party. J Clin Oncol. 2005;23:9219–9226.
   PubMed Web of Science ®Google Scholar
• Kim JE, Yoo C, Lee DH, et al. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89:391–397.
   PubMed Web of Science ®Google Scholar
• Mussap M, Merlini G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media? BioMed Res Int. 2014;2014:167125. doi: 10.1155/2014/167125
   PubMed Web of Science ®Google Scholar
• Woodruff R, Sweet B. Multiple myeloma with massive bence jones proteinuria and preservation of renal function. N Z J Med New J. 1977;7:60–62.
   Web of Science ®Google Scholar
• Wang P, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol. 2007;18:1239–1245.
   PubMed Web of Science ®Google Scholar
• Bergsagel DE, Migliore PI, Griffith KM. Myeloma proteins and the clinical response to melphalan therapy. Science. 1965;148:376–377.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–3131.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775–779.
   PubMed Web of Science ®Google Scholar